ClinicalTrials.gg
CompletedNCT00784654Updated Jun 9, 2021Results posted

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

A Phase 3 interventional study of Lisdexamfetamine dimesylate (LDX) and Placebo in ADHD, sponsored by Shire. Completed at 51 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
10th of 51
276 · median 48
Started
2009
with 5 others
Phase 3
15 of 51
none open now
Registered
17th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 10th largest by enrollment, is one of 6 that started in 2009, is one of 15 in phase 3, and was the 17th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months

03

Conditions studied

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's parent or legally authorised representative(LAR) must provide signature of , and there must be documentation of assent (if applicable) by the subject indicating that the subject is aware of the nature of the study and the required procedures and restrictions in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations before completing any study-related procedures.
  2. Subject and parent/LAR are willing and able to comply with all the testing and requirements defined in this protocol, including oversight of morning dosing. Specifically, the parent/LAR must be available upon awakening, at approximately 7:00AM, to dispense the dose of test product for the duration of the study.
  3. Subject is a male or female aged 6-17 years inclusive at the time of consent for the antecedent study (SPD489-325).
  4. Subject satisfied all entry criteria for the antecedent study (SPD489-325), and completed a minimum of 4 weeks of double-blind treatment, reached Visit 4 and completed the 1-week post-treatment in the antecedent study (SPD489-325), without experiencing any AEs that would preclude exposure to LDX.
  5. Subject must have a satisfactory medical assessment with no clinically significant or relevant abnormalities as determined by medical history, physical examination findings and clinical laboratory test results.
  6. Subject has blood pressure measurements within the 95th percentile for age, gender, and height.

Exclusion criteria

Exclusion Criteria:

  1. Subject was terminated from SPD489-325 for non-compliance and/or experienced an SAE or AE resulting in termination from the antecedent study.
  2. Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorder or severe Axis I disorder (such as Post Traumatic Stress Disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder) or other symptomatic manifestations, such as agitated states, marked anxiety, or tension that, in the opinion of the examining clinician, will contraindicate treatment with LDX or confound efficacy or safety assessments. Comorbid psychiatric diagnoses will be established at the Screening Visit (Visit -1)of the antecedent study (SPD489-325)with the Screening interview of the Kiddie-SADS-Present and Lifetime-Diagnostic Interview (K-SADS-PL)and additional modules if warranted by the results of the initial interview. Participation in behavioural therapy is permitted provided the subject was receiving the therapy for at least 1 month at the time of the Baseline Visit (Visit 0) of the antecedent study (SPD489-325).
  3. Subject has a conduct disorder. Oppositional defiant disorder is not exclusionary.
  4. Subject has any concurrent chronic or acute illness or unstable medical condition that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol.
  5. Subject is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently, demonstrating active suicidal ideation.
  6. Subject is female and is pregnant or lactating.
  7. Subject has glaucoma.
  8. Subject has any at Visit 8 of the antecedent study (SPD489-325) or clinically significant laboratory abnormalities at Visit 7 of the antecedent study (SPD489-325).
  9. Subject has a documented allergy, , or intolerance to amphetamine.
  10. Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine)in accordance with the , Fourth Edition - Text Revision (DSM-IV-TR)criteria.
  11. Subject has a history of seizures (other than infantile febrile seizures), a tic disorder, a current diagnosis and or a known family history of Tourette's Disorder.
  12. Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  13. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  14. Subject is taking any medication that is excluded.
  15. Subject is taking other medications that have central nervous system (CNS) effects, affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors (during or within 14 days of medicinal product administration). Stable use of bronchodilator inhalers is not exclusionary.
  16. Subject has a documented allergy, hypersensitivity, or intolerance to any in the investigational medicinal product(s).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine dimesylate (LDX)

    Open-label 30, 50, or 70mg

    Drug: Lisdexamfetamine dimesylate (LDX)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)

    Also known as: Vyvanse, SPD489

  • DrugPlacebo

    Placebo capsule once per day (double-blind period)

06

What researchers measure

Primary outcomes

  1. Percent of Participants With Treatment Failures at End of The Randomized Withdrawal Period

    Treatment failure defined as 50% increase (worsening) in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) total score and \>= 2 point increase (worsening) in the Clinical Global Impression-Severity of Illness (CGI-S) score observed at any visit during the randomized withdrawal period compared to the respective scores at baseline of randomized withdrawal period. Subjects without an endpoint value were classed as treatment failures.

    Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)

Secondary outcomes

  1. Change From Open-Label Baseline in The Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at Endpoint (Week-26) of The Open-label Period

    ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

    Time frame: Open-label baseline and Endpoint (Week-26)

  2. Change From Randomized Withdrawal Baseline in The ADHD-RS-IV Total Score at Endpoint of The Randomized Withdrawal Period

    ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

    Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)

  3. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: At Week 26

  4. Percent of Participants With CGI-S at Endpoint of The Randomized Withdrawal Period, Last Observation Carried Forward (LOCF)

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: At endpoint of the randomized withdrawal period (Up to 6 weeks)

  5. Percent of Participants With Improvement on Clinical Global Impression - Improvement (CGI-I) at Endpoint (Week-26) of The Open-label Period

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Improvement includes CGI-I categories of very much improved and much improved. No improvement includes all other assessed categories.

    Time frame: At Week 26

  6. Change From Open-label Baseline in The Health Utilities Index-2 (HUI-2) Scores at Endpoint (Week-26) of The Open-label Period, LOCF

    HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

    Time frame: At open-label baseline and endpoint (Week-26) of the open-label period

  7. Change From Randomized Withdrawal Baseline in The HUI-2 Scores at Endpoint of The Randomized Withdrawal Period

    HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

    Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)

  8. Change From Open-label Baseline in The Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at Endpoint (Week-26) of The Open-label Period

    The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.

    Time frame: At open-label baseline and endpoint (Week-26) of the open-label period

  9. Change From Randomized Withdrawal Baseline in The CHIP-CE:PRF Global T-score at Endpoint of The Randomized Withdrawal Period

    The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.

    Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)

  10. Change From Open-Label Baseline in The Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Endpoint (Week-26) of The Open-label Period

    The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

    Time frame: At open-label baseline and endpoint (Week-26) of the open-label period

  11. Change From Randomized Withdrawal Baseline in The WFIRS-P Global Score at Endpoint of The Randomized Withdrawal Period

    The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

    Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)

  12. Change From Open-Label Baseline in The Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Endpoint (Week-26) of The Open-label Period

    The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

    Time frame: At open-label baseline and endpoint (Week-26) of the open-label period

  13. Change From Randomized Withdrawal Baseline in BPRS-C Total Score at Endpoint of The Randomized Withdrawal Period

    The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

    Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)

Other outcomes

  1. Percent of Participants With CGI-S at Open-label Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).

    Time frame: Open-label baseline

  2. Percent of Participants With CGI-S at Randomized Withdrawal Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Randomized withdrawal baseline

  3. Columbia-Suicide Severity Rating Scale (C-SSRS) During The Open-label Period

    C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

    Time frame: From open-label baseline to Week-26

  4. C-SSRS During the Randomized Withdrawal Period

    C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

    Time frame: Baseline of the randomized withdrawal period to end of the study (Up to 6 weeks)

07

Results

Posted Oct 2, 2012

Participant flow

Open-Label Period (Non-Randomized)
Participant flow — Open-Label Period (Non-Randomized)
MilestoneLisdexamfetamine Dimesylate (LDX)(Open-label Period)Lisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Started27600
Completed16500
Not completed11100
Withdrew: Adverse event4400
Withdrew: Withdrawal by subject2200
Withdrew: Lack of efficacy2100
Withdrew: Lost to follow-up1100
Withdrew: Protocol violation700
Withdrew: Mother is a drug addict100
Withdrew: Decision of medical monitor100
Withdrew: Home situation intolerable100
Withdrew: Adhd-rs score too high for random phase100
Withdrew: Met stopping criteria for cgi-s score100
Withdrew: Did not provide end of study page100
Randomized Withdrawal Period
Participant flow — Randomized Withdrawal Period
MilestoneLisdexamfetamine Dimesylate (LDX)(Open-label Period)Lisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Started07879
Completed06016
Not completed01863
Withdrew: Met relapse criteria per investigator0835
Withdrew: Lack of efficacy0518
Withdrew: Withdrawal by subject017
Withdrew: Protocol violation021
Withdrew: Adverse event011
Withdrew: Did not complete a visit010
Withdrew: Family reasons001

Outcome measures

PrimaryPercent of Participants With Treatment Failures at End of The Randomized Withdrawal Period

Treatment failure defined as 50% increase (worsening) in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) total score and \>= 2 point increase (worsening) in the Clinical Global Impression-Severity of Illness (CGI-S) score observed at any visit during the randomized withdrawal period compared to the respective scores at baseline of randomized withdrawal period. Subjects without an endpoint value were classed as treatment failures.

Time frame:
Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Reported as:
Number · percentage of participants
Percent of Participants With Treatment Failures at End of The Randomized Withdrawal Period
percentage of participantsLisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Percent of Participants With Treatment Failures at End of The Randomized Withdrawal Period15.867.5
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX)(Randomized Period) vs Placebo (Randomized Period) · Cochran-Mantel-Haenszel · p = < 0.001
SecondaryChange From Open-Label Baseline in The Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at Endpoint (Week-26) of The Open-label Period

ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

Time frame:
Open-label baseline and Endpoint (Week-26)
Reported as:
Mean · Scores on a scale
Change From Open-Label Baseline in The Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at Endpoint (Week-26) of The Open-label Period
Scores on a scaleLisdexamfetamine Dimesylate (LDX)(Open-label Period)
Change From Open-Label Baseline in The Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at Endpoint (Week-26) of The Open-label Period-26.6 ± 11.39
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX)(Open-label Period) · t-test, 2 sided · p = <0.001
SecondaryChange From Randomized Withdrawal Baseline in The ADHD-RS-IV Total Score at Endpoint of The Randomized Withdrawal Period

ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

Time frame:
Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Reported as:
Least squares mean · Scores on a scale
Change From Randomized Withdrawal Baseline in The ADHD-RS-IV Total Score at Endpoint of The Randomized Withdrawal Period
Scores on a scaleLisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Change From Randomized Withdrawal Baseline in The ADHD-RS-IV Total Score at Endpoint of The Randomized Withdrawal Period1.2 ± 1.0913.8 ± 1.06
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX)(Randomized Period) vs Placebo (Randomized Period) · ANCOVA · p = <0.001 · Mean difference (final values): -12.6 · 95% CI -15.4 to -9.8
SecondaryPercent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
At Week 26
Reported as:
Number · percentage of participants
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period
percentage of participantsLisdexamfetamine Dimesylate (LDX)(Open-label Period)
Normal, not at all ill39.9
Borderline mentally ill46.5
Mildly ill1.5
Moderately ill6.6
Markedly ill4.5
Severely ill0.5
Among the most extremely ill0.5
Other pre-specifiedPercent of Participants With CGI-S at Open-label Baseline

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).

Time frame:
Open-label baseline
Reported as:
Number · percentage of participants
Percent of Participants With CGI-S at Open-label Baseline
percentage of participantsLisdexamfetamine Dimesylate (LDX)(Open-label Period)
Normal, not at all ill0
Borderline mentally ill0
Mildly ill1.5
Moderately ill27.2
Markedly ill50.2
Severely ill17.6
Among the most extremely ill3.4
SecondaryPercent of Participants With CGI-S at Endpoint of The Randomized Withdrawal Period, Last Observation Carried Forward (LOCF)

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
At endpoint of the randomized withdrawal period (Up to 6 weeks)
Reported as:
Number · percentage of participants
Percent of Participants With CGI-S at Endpoint of The Randomized Withdrawal Period, Last Observation Carried Forward (LOCF)
percentage of participantsLisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Normal, not at all ill40.08.2
Borderline mentally ill41.319.2
Mildly ill8.011.0
Moderately ill10.739.7
Markedly ill015.1
Severely ill06.8
Among the most extremely ill00
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX)(Randomized Period) vs Placebo (Randomized Period) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercent of Participants With Improvement on Clinical Global Impression - Improvement (CGI-I) at Endpoint (Week-26) of The Open-label Period

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Improvement includes CGI-I categories of very much improved and much improved. No improvement includes all other assessed categories.

Time frame:
At Week 26
Reported as:
Number · percentage of improved participants
Percent of Participants With Improvement on Clinical Global Impression - Improvement (CGI-I) at Endpoint (Week-26) of The Open-label Period
percentage of improved participantsLisdexamfetamine Dimesylate (LDX)(Open-label Period)
Percent of Participants With Improvement on Clinical Global Impression - Improvement (CGI-I) at Endpoint (Week-26) of The Open-label Period79.8
SecondaryChange From Open-label Baseline in The Health Utilities Index-2 (HUI-2) Scores at Endpoint (Week-26) of The Open-label Period, LOCF

HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

Time frame:
At open-label baseline and endpoint (Week-26) of the open-label period
Reported as:
Mean · scores on a scale
Change From Open-label Baseline in The Health Utilities Index-2 (HUI-2) Scores at Endpoint (Week-26) of The Open-label Period, LOCF
scores on a scaleLisdexamfetamine Dimesylate (LDX)(Open-label Period)
Change From Open-label Baseline in The Health Utilities Index-2 (HUI-2) Scores at Endpoint (Week-26) of The Open-label Period, LOCF0.087 ± 0.1307
SecondaryChange From Randomized Withdrawal Baseline in The HUI-2 Scores at Endpoint of The Randomized Withdrawal Period

HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

Time frame:
Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Reported as:
Mean · Scores on a scale
Change From Randomized Withdrawal Baseline in The HUI-2 Scores at Endpoint of The Randomized Withdrawal Period
Scores on a scaleLisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Change From Randomized Withdrawal Baseline in The HUI-2 Scores at Endpoint of The Randomized Withdrawal Period-0.005 ± 0.0772-0.046 ± 0.1098
SecondaryChange From Open-label Baseline in The Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at Endpoint (Week-26) of The Open-label Period

The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.

Time frame:
At open-label baseline and endpoint (Week-26) of the open-label period
Reported as:
Mean · T-scores
Change From Open-label Baseline in The Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at Endpoint (Week-26) of The Open-label Period
T-scoresLisdexamfetamine Dimesylate (LDX)(Open-label Period)
Change From Open-label Baseline in The Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at Endpoint (Week-26) of The Open-label Period10.2 ± 10.71
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX)(Open-label Period) · t-test, 1 sided · p = <0.001
SecondaryChange From Randomized Withdrawal Baseline in The CHIP-CE:PRF Global T-score at Endpoint of The Randomized Withdrawal Period

The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.

Time frame:
Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Reported as:
Least squares mean · T-scores
Change From Randomized Withdrawal Baseline in The CHIP-CE:PRF Global T-score at Endpoint of The Randomized Withdrawal Period
T-scoresLisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Change From Randomized Withdrawal Baseline in The CHIP-CE:PRF Global T-score at Endpoint of The Randomized Withdrawal Period1.1 ± 1.17-5.4 ± 1.10
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX)(Randomized Period) vs Placebo (Randomized Period) · ANCOVA · p = <0.001 · Mean difference (final values): 6.5 · 95% CI 3.5 to 9.5
SecondaryChange From Open-Label Baseline in The Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Endpoint (Week-26) of The Open-label Period

The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

Time frame:
At open-label baseline and endpoint (Week-26) of the open-label period
Reported as:
Mean · scores on a scale
Change From Open-Label Baseline in The Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Endpoint (Week-26) of The Open-label Period
scores on a scaleLisdexamfetamine Dimesylate (LDX)(Open-label Period)
Change From Open-Label Baseline in The Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Endpoint (Week-26) of The Open-label Period-0.43 ± 0.42
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX)(Open-label Period) · t-test, 1 sided · p = <0.001
SecondaryChange From Randomized Withdrawal Baseline in The WFIRS-P Global Score at Endpoint of The Randomized Withdrawal Period

The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

Time frame:
Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Reported as:
Least squares mean · Scores on a scale
Change From Randomized Withdrawal Baseline in The WFIRS-P Global Score at Endpoint of The Randomized Withdrawal Period
Scores on a scaleLisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Change From Randomized Withdrawal Baseline in The WFIRS-P Global Score at Endpoint of The Randomized Withdrawal Period0.01 ± 0.030.20 ± 0.03
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX)(Randomized Period) vs Placebo (Randomized Period) · ANCOVA · p = <0.001 · Mean difference (final values): -0.19 · 95% CI -0.26 to -0.11
SecondaryChange From Open-Label Baseline in The Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Endpoint (Week-26) of The Open-label Period

The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

Time frame:
At open-label baseline and endpoint (Week-26) of the open-label period
Reported as:
Mean · Scores on a scale
Change From Open-Label Baseline in The Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Endpoint (Week-26) of The Open-label Period
Scores on a scaleLisdexamfetamine Dimesylate (LDX)(Open-label Period)
Change From Open-Label Baseline in The Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Endpoint (Week-26) of The Open-label Period-13.9 ± 12.58
SecondaryChange From Randomized Withdrawal Baseline in BPRS-C Total Score at Endpoint of The Randomized Withdrawal Period

The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

Time frame:
Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Reported as:
Mean · Scores on a scale
Change From Randomized Withdrawal Baseline in BPRS-C Total Score at Endpoint of The Randomized Withdrawal Period
Scores on a scaleLisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Change From Randomized Withdrawal Baseline in BPRS-C Total Score at Endpoint of The Randomized Withdrawal Period-17.1 ± 11.17-9.1 ± 11.26
Other pre-specifiedPercent of Participants With CGI-S at Randomized Withdrawal Baseline

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Randomized withdrawal baseline
Reported as:
Number · percentage of participants
Percent of Participants With CGI-S at Randomized Withdrawal Baseline
percentage of participantsLisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Normal, not at all ill50.046.8
Borderline mentally ill50.053.2
Mildly ill00
Moderately ill00
Markedly ill00
Severely ill00
Among the most extremely ill00
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX)(Randomized Period) vs Placebo (Randomized Period) · Cochran-Mantel-Haenszel · p = 0.726
Other pre-specifiedColumbia-Suicide Severity Rating Scale (C-SSRS) During The Open-label Period

C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

Time frame:
From open-label baseline to Week-26
Reported as:
Number · participants
Columbia-Suicide Severity Rating Scale (C-SSRS) During The Open-label Period
participantsLisdexamfetamine Dimesylate (LDX)(Open-label Period)
Suicidal ideation1
Suicidal behavior0
Other pre-specifiedC-SSRS During the Randomized Withdrawal Period

C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

Time frame:
Baseline of the randomized withdrawal period to end of the study (Up to 6 weeks)
Reported as:
Number · participants
C-SSRS During the Randomized Withdrawal Period
participantsLisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Suicidal ideation00
Suicidal behavior00

Adverse events

Collected over 33 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisdexamfetamine Dimesylate (LDX)(Open-label Period)—12/276 (4.3%)227/276 (82.2%)
Lisdexamfetamine Dimesylate (LDX)(Randomized Period)—0/78 (0%)31/78 (39.7%)
Placebo (Randomized Period)—1/79 (1.3%)20/79 (25.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventLisdexamfetamine Dimesylate (LDX)(Open-label Period)Lisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Attention deficit/hyperactivity disorderPsychiatric disorders0/2760/781/79
SyncopeNervous system disorders2/2760/780/79
AggressionPsychiatric disorders2/2760/780/79
Abdominal painGastrointestinal disorders1/2760/780/79
VomitingGastrointestinal disorders1/2760/780/79
CellulitisInfections and infestations1/2760/780/79
Gastric infectionInfections and infestations1/2760/780/79
WoundInjury, poisoning and procedural complications1/2760/780/79
DehydrationMetabolism and nutrition disorders1/2760/780/79
Abnormal behaviorPsychiatric disorders1/2760/780/79
Most frequent other events
Showing 10 of 30
Most frequent other events
EventLisdexamfetamine Dimesylate (LDX)(Open-label Period)Lisdexamfetamine Dimesylate (LDX)(Randomized Period)Placebo (Randomized Period)
Decreased appetiteMetabolism and nutrition disorders76/2763/780/79
HeadacheNervous system disorders58/2766/785/79
Weight decreasedInvestigations46/2762/781/79
NasopharyngitisInfections and infestations43/2767/783/79
AnorexiaMetabolism and nutrition disorders41/2760/780/79
InsomniaPsychiatric disorders39/2761/781/79
VomitingGastrointestinal disorders32/2762/781/79
NauseaGastrointestinal disorders27/2762/780/79
Abdominal pain upperGastrointestinal disorders23/2764/782/79
Abdominal painGastrointestinal disorders20/2762/780/79

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled Subjects
Mean10.9 ± 2.82
Age, Customized
Age, Customized(Participants)All Enrolled Subjects
6-12 years191
13-17 years85
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled Subjects
Female64
Male212
Region of Enrollment
Region of Enrollment(Participants)All Enrolled Subjects
United States40
Italy20
United Kingdom16
France11
Hungary28
Belgium9
Poland8
Germany95
Sweden49
08

Study locations

51 sites
  • Peninsula Research Associates, Inc.
    Rolling Hills Estates, California 66212, United States
  • Miami Research Associates
    South Miami, Florida 47802, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 23112, United States
  • CNS Healthcare
    Memphis, Tennessee 38119, United States
  • ZNA Antwerpen, Commandant Weynsstraat 165
    Hoboken, Antwerpen 2660, Belgium
  • Afdeling Psychiatrie, UZ Herestraat 49
    Leuven, Flemish Brabant B-3000, Belgium
  • Universitair Ziekenhuis Gent, Kinder - en Jeugdpsychiatrie
    Ghent, Oost-vlaanderen 9000, Belgium
  • Hôpital Robert Debré
    Paris, Ile-de-france 75019, France
  • Hôpital Gui de Chauliac
    Montpellier Cedex 05, 34295, France
  • Hospital Archet 2
    Nice Cedex 03, 06202, France
  • Albert-Ludwigs-Universitat Freiburg
    Freiburg, Baden-wuttemberg 79104, Germany
  • Zentralinstitut für Seelische Gesundheit Mannheim
    Mannheim, Baden-wuttemberg 68159, Germany
  • Schwerpunktpraxis für Entwicklung und Lernen
    Bamberg, Bayern 96047, Germany
  • Medizinisches Studienzentrum Würzburg
    Würzburg, Bayern 97070, Germany
  • Universität Würzburg
    Würzburg, Bayern 97080, Germany
  • Institutsambulanz Bad Nauheim
    Bad Nauheim, Hessen 61231, Germany
  • Universitat Göttingen
    Göttingen, Niedersachsen 37075, Germany
  • Universität zu Köln, Klinik und Poliklinik für Psychiatrie und Psychotherapie des Kindes und Jugendalters
    Köln, Nordrhein-westfalen 50931, Germany
  • Klinikum der Johannes Gutenberg-Universität Mainz
    Mainz, Rheinland-pfalz 55131, Germany
  • Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Praxis Dr. Walter Robert Otto
    Fulda, 36037, Germany
  • Praxis Dr. Wolff
    Hagen, 58093, Germany
  • Praxis für Neuropädiatrie
    Hamburg, 22767, Germany
  • Praxis Dr med. Friedrich Kaiser und Dr. med. Ingrid Marinesse
    Hamburg, D-22415, Germany
  • Universitätsklinikum Gießen und Marburg GmbH, Universitätsklinikum Gießen und Marburg GmbH, Hans-Sachs-Straße 4,
    Marburg, 35039, Germany
  • Vadaskert Kórház és Szakambulancia
    Budapest, 1021, Hungary
  • Pándy Kálmán Kórház
    Gyula, 5700, Hungary
  • Gyermek és Ifjúságpszichiátriai Szakrendelés és Gondozó
    Pécs, 7632, Hungary
  • Szegedi Tudományegyetem
    Szeged, 6750, Hungary
  • Azienda Ospedaliera Policlinico Consorziale
    Bari, 70124, Italy
  • Università degli Studi di Cagliari
    Cagliari, 9124, Italy
  • Azienda Ospedaliera Universitaria Policlinico G. Martino
    Messina, 98125, Italy
  • Azienda Ospedaliera della 2? Universita di Napoli
    Napoli, 80131, Italy
  • Szpital Uniwersytecki im. dr. Antoniego Jurasza w Bydgoszczy
    Bydgoszcz, Kujawsko-pomorskie 85-094, Poland
  • Wojewódzki Osrodek Lecznictwa Psychiatrycznego
    Torun, Kujawsko-pomorskie 87-100, Poland
  • Samodzielny Publiczny Dzieciecy Szpital Kliniczny, Poradnia Psychiatryczna, ul. Marszalkowska 24,
    Warszawa, Mazowieckie 00-576, Poland
  • Gdanski Uniwersytet Medyczna w Gdansku
    Gdansk, Pomorskie 80-282, Poland
  • Specjalistyczna Praktyka Lekarska
    Poznan, Wielkopolskie 60-792, Poland
  • Drottning Silvias Barnsjukhus, Otterhällegatan 12A
    Goteborg, 41119, Sweden
  • Utvecklingsneurologiska Enheten (UNE)
    Mariestad, 542 24, Sweden
  • Astrid Lindgren Children's Hospital, Karolinska University Hospital
    Stockholm, 171 76, Sweden
  • Barn och Ungdomsmedicin klinik Mölnlycke
    Stockholm, 435 30, Sweden
  • Parkview Clinic
    Birmingham, England B13 8QE, United Kingdom
  • East Kent NHS and Social Care Partnership Trust
    Ramsgate, England CT11 9DH, United Kingdom
  • Lighthouse Child Development Centre
    Southend-on-Sea, Essex SS2 6XT, United Kingdom
  • Victoria Hospital, Paediatric Unit
    Kirkcaldy, Fife KY2 5AH, United Kingdom
  • Tayside Children's Hospital
    Dundee, Scotland DD1 9SY, United Kingdom
  • Ryegate Children's Centre
    Sheffield, Yorkshire S10 5DD, United Kingdom
  • Basildon Hospital - Child Development Centre,
    Basildon, SS16 5NL, United Kingdom
  • Northampton Child and Adolescent Mental Health Services
    Northampton, NN1 2BG, United Kingdom
  • Child and Family Mental Health Services
    Wigan, WN2 2JA, United Kingdom
09

References and documents

Publications

  • Banaschewski T, Johnson M, Lecendreux M, Zuddas A, Adeyi B, Hodgkins P, Squires LA, Coghill DR. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs. 2014 Dec;28(12):1191-203. doi: 10.1007/s40263-014-0193-z. PubMed 25139785 ↗
  • Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, Civil R, Dauphin M, Higgins N, Lyne A, Gasior M, Squires LA. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014 Jun;53(6):647-657.e1. doi: 10.1016/j.jaac.2014.01.017. Epub 2014 Mar 4. PubMed 24839883 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2009 to primary completion in Oct 2011, 32 months.

Results were first posted in Oct 2012, 11 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 32 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2008
First posted
Nov 4, 2008
StartActual
Jan 27, 2009
Primary completionActual
Oct 26, 2011
CompletionActual
Oct 26, 2011
Results first posted
Oct 2, 2012
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00784654
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Nov 4, 2008
Start date
Jan 27, 2009
Primary completion
Oct 26, 2011
Completion
Oct 26, 2011
Results posted
Oct 2, 2012
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion